3. Pharmacological treatment for nystagmus.

Study ID	Total participants	Primary: improved ocular motility	Secondary: improved visual acuity	Secondary: improved symptoms	Secondary: adverse events
Averbuch‐Heller 1997	21, crossover RCT 15 ‐ pendular 6 ‐ jerk 6‐week trial duration	15 pendular ‐ gabapentin	15 pendular ‐ gabapentin 1 jerk ‐ gabapentin 1 jerk ‐ baclofen	6 pendular ‐ gabapentin 1 jerk ‐ gabapentin 1 jerk ‐ baclofen	1 drug intolerance ‐ gabapentin 4 drug intolerance ‐ baclofen 3 ataxia ‐ gabapentin 2 ataxia ‐ baclofen
Kalla 2011	8, crossover RCT 8 ‐ downbeat 8‐day trial duration	Baseline ‐6.04; 45 mins ‐1.58; 90 mins ‐1.21 (4‐aminopyridine) Baseline ‐5.68; 45 mins ‐3.29; 90 mins ‐2.96 (3,4‐diaminopyridine)	‐	‐	All with mild paraesthesia
Strupp 2003	17, crossover RCT 17 ‐ downbeat 16‐day trial duration	Baseline 7.2 ± 4.2 °/sec reducing to 3.1 ± 2.5 (3,4‐diaminopyridine) Baseline 7.4 ± 4.1 °/sec reducing to 7.3 ± 3.7 (placebo)	‐	10 ‐ reduced symptoms (3,4‐diaminopyridine) 0 ‐ reduced symptoms (placebo)	3 ‐ mild paraesthesia (3,4‐diaminopyridine) 1 ‐ nausea/headache (3,4‐diaminopyridine)

RCT: randomised controlled trial